{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Antineoplastic+Agents&page=4", "query": { "condition": "Antineoplastic Agents", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 256, "total_pages": 26, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Antineoplastic+Agents&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Antineoplastic+Agents&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-03T05:10:29.179Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02171221", "title": "Phase I Study of Oral DFP-11207 in Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Cancer" ], "interventions": [ { "name": "Oral DFP-11207", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Delta-Fly Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2014-06", "completion_date": "2018-09-13", "has_results": false, "last_update_posted_date": "2019-01-29", "last_synced_at": "2026-10-03T05:10:29.179Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02171221" }, { "nct_id": "NCT00002189", "title": "Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma, Kaposi", "HIV Infections" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baker Norton Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-03T05:10:29.179Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002189" }, { "nct_id": "NCT01920061", "title": "A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm" ], "interventions": [ { "name": "PF-05212384 (gedatolisib)", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Dacomitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2013-09-10", "completion_date": "2020-01-08", "has_results": true, "last_update_posted_date": "2022-09-13", "last_synced_at": "2026-10-03T05:10:29.179Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01920061" }, { "nct_id": "NCT00002136", "title": "A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma, Kaposi", "HIV Infections" ], "interventions": [ { "name": "Tecogalan sodium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-03T05:10:29.179Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002136" }, { "nct_id": "NCT01204801", "title": "Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Focused Microwave Thermotherapy", "type": "DEVICE" }, { "name": "Chemotherapy (control)", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Medifocus, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 238, "start_date": "2010-11", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2015-09-24", "last_synced_at": "2026-10-03T05:10:29.179Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT01204801" }, { "nct_id": "NCT00000689", "title": "Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Non-Hodgkin", "HIV Infections" ], "interventions": [ { "name": "Bleomycin sulfate", "type": "DRUG" }, { "name": "Vincristine sulfate", "type": "DRUG" }, { "name": "Doxorubicin hydrochloride", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Leucovorin calcium", "type": "DRUG" }, { "name": "Sargramostim", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 18, "start_date": null, "completion_date": "1991-03", "has_results": false, "last_update_posted_date": "2021-11-02", "last_synced_at": "2026-10-03T05:10:29.179Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000689" }, { "nct_id": "NCT02551055", "title": "MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma" ], "interventions": [ { "name": "MLN1117", "type": "DRUG" }, { "name": "TAK-659", "type": "DRUG" }, { "name": "Alisertib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2015-10-15", "completion_date": "2017-02-17", "has_results": true, "last_update_posted_date": "2019-09-20", "last_synced_at": "2026-10-03T05:10:29.179Z", "location_count": 5, "location_summary": "Lake Success, New York • New York, New York • Philadelphia, Pennsylvania + 2 more", "locations": [ { "city": "Lake Success", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02551055" }, { "nct_id": "NCT05123482", "title": "A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Biliary Tract Carcinoma", "Ovarian Cancer", "Endometrial Cancer", "Squamous Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "AZD8205", "type": "DRUG" }, { "name": "AZD8205 and AZD2936 (Rilvegostomig)", "type": "DRUG" }, { "name": "AZD8205 and AZD5305 (saruparib)", "type": "DRUG" }, { "name": "AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)", "type": "DRUG" }, { "name": "AZD8205 in combination with AZD9574", "type": "DRUG" }, { "name": "AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 460, "start_date": "2021-10-18", "completion_date": "2027-09-29", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-03T05:10:29.179Z", "location_count": 14, "location_summary": "Duarte, California • Irvine, California • Santa Monica, California + 11 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Shreveport", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05123482" }, { "nct_id": "NCT04711252", "title": "A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "ER-Positive HER2-Negative Breast Cancer" ], "interventions": [ { "name": "AZD9833", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Anastrozole placebo", "type": "DRUG" }, { "name": "AZD9833 placebo", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Luteinizing hormone-releasing hormone (LHRH) agonist", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 1371, "start_date": "2021-01-28", "completion_date": "2029-02-01", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-03T05:10:29.179Z", "location_count": 30, "location_summary": "Mobile, Alabama • Springdale, Arkansas • Harbor City, California + 25 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Harbor City", "state": "California" }, { "city": "Solvang", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04711252" }, { "nct_id": "NCT05153408", "title": "(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Neoplasm", "Carcinoma, Non-Small-Cell Lung", "Respiratory Tract Neoplasms", "Neoplasms", "Neoplasms by Site", "Lung Diseases", "Respiratory Tract Diseases", "Carcinoma, Bronchogenic", "Bronchial Neoplasms", "Adenocarcinoma", "Carcinoma", "Neoplasms by Histologic Type", "Neoplasms, Nerve Tissue", "EGFR C797S", "EGFR C797A", "EGFR L858R", "EGFR Exon 19 Deletion", "EGFR Gene Mutation", "EGF-R Positive Non-Small Cell Lung Cancer", "EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance", "EGFR Activating Mutation", "Thoracic Neoplasms", "Antineoplastic Agents", "Protein Kinase Inhibitors", "EGFR C797G", "EGFR C797X", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "BLU-701", "type": "DRUG" }, { "name": "osimertinib", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Blueprint Medicines Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2022-01-13", "completion_date": "2022-12-09", "has_results": false, "last_update_posted_date": "2023-06-18", "last_synced_at": "2026-10-03T05:10:29.179Z", "location_count": 7, "location_summary": "Boston, Massachusetts • Detroit, Michigan • New York, New York + 3 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05153408" } ] }